ArticleNPJ precision oncology2023

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.

Heidi J Gray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.